Quoin Pharmaceuticals Business Summary

Quoin Pharmaceuticals, Ltd. (QNRX) is a clinical-stage specialty pharmaceutical company that generates revenue through a hybrid model of future product commercialization, strategic licensing, and milestone-based partnerships. The company focuses on the development of therapeutic products for rare and orphan diseases, primarily within the dermatology segment. Its lead candidate, QRX003, is a topical lotion in pivotal clinical trials for Netherton Syndrome, with a pipeline extending to Peeling Skin Syndrome and Epidermolysis Bullosa. Quoin’s commercial strategy involves establishing internal sales infrastructure in the U.S., Western Europe, and Japan, while leveraging a network of strategic partnerships spanning 61 countries to maximize global market penetration. In the competitive landscape, Quoin contends with Azitra, Krystal Biotech, and PellePharm; it distinguishes itself by targeting indications with no currently approved treatments and utilizing a proprietary drug delivery technology to optimize topical efficacy. The leadership team is anchored by Co-Founder and CEO Dr. Michael Myers, who brings over 38 years of industry experience, including his previous tenure as CEO of Innocoll, where he led the company’s IPO. He is joined by Co-Founder and COO Denise Carter, a veteran of the drug delivery sector with executive experience at West Pharmaceutical Services and Fuisz Technologies. In August 2025, the company strengthened its financial oversight by appointing Sally Lawlor as CFO, who previously held senior roles at Sebela Pharmaceuticals and KPMG. Quoin is backed by a consortium of healthcare-focused institutional investors, including Altium Capital Management, AIGH Capital Management, Soleus Capital, and Nantahala Capital, following a significant $105.3 million private placement in late 2025 intended to fund operations and clinical milestones through 2027.